View Older Stories View More Recent Stories

Jul 24, 2020 08:30AM Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors
Jul 23, 2020 08:00AM Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
Jul 14, 2020 05:51AM Blueprint Medicines (BPMC) Enters Global Collaboration with Roche to Develop & Commercialize Pralsetinib for Patients with RET-Altered Cancers
Jul 14, 2020 01:00AM Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
Jul 2, 2020 04:01PM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 1, 2020 08:03AM Blueprint Medicines (BPMC) Announces Submission of NDA to FDA for Pralsetinib for Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
Jul 1, 2020 08:00AM Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers
Jun 29, 2020 06:30PM Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST
Jun 6, 2020 09:00AM Blueprint Medicines Presents Updated Part 1 Data from PIONEER Trial of Avapritinib Showing Robust Reductions in Cutaneous Disease Symptoms in Patients with Indolent Systemic Mastocytosis
Jun 3, 2020 08:00AM Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 29, 2020 08:14AM Blueprint Medicines (BPMC) Presents Data from Ongoing ARROW Clinical Trial of Pralsetinib in Patients w/ RET Fusion-Positive NSCLC, Thyroid Cancer & Other Solid Tumors
May 29, 2020 08:00AM Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumor
May 26, 2020 08:00AM Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020
May 15, 2020 08:01AM Blueprint Medicines (BPMC) Receives CRL from FDA for Avapritinib NDA for Treatment of Fourth-Line Gastrointestinal Stromal Tumor
May 15, 2020 08:00AM Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
May 14, 2020 09:00AM Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs
May 6, 2020 07:00AM Blueprint Medicines Reports First Quarter 2020 Financial Results
Apr 29, 2020 08:00AM Blueprint Medicines to Report First Quarter 2020 Financial Results on Wednesday, May 6, 2020
Apr 28, 2020 07:01AM Blueprint Medicines (BPMC) VOYAGER trial of Avapritinib did not meet primary endpoint
Apr 28, 2020 07:00AM Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
Apr 1, 2020 08:00AM Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
Mar 16, 2020 07:08AM Blueprint Medicines (BPMC) Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Syst
Mar 16, 2020 07:00AM Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Ma
Mar 9, 2020 09:00AM Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020
Feb 24, 2020 04:05PM Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting
Feb 19, 2020 08:00AM Blueprint Medicines to Present at Upcoming Investor Conferences
Feb 13, 2020 07:00AM Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 6, 2020 04:05PM Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
Feb 6, 2020 08:18AM Blueprint Medicines (BPMC) Announces PDUFA Date Extension for NDA of Avapritinib for Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor
Feb 6, 2020 08:00AM Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor
Jan 13, 2020 08:00AM Blueprint Medicines Announces 2020 Corporate Goals
Jan 9, 2020 03:53PM Blueprint Medicines (BPMC) Confirms FDA Approval of AYVAKIT for Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Jan 9, 2020 03:52PM Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Jan 8, 2020 08:05AM Blueprint Medicines (BPMC) Reports Top-Line Data from Pralsetinib; Begins Rolling NDA Submission to FDA
Jan 8, 2020 08:00AM Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
Jan 6, 2020 08:05AM Blueprint Medicines (BPMC), CStone Pharmaceuticals Begin Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
Jan 6, 2020 08:00AM CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
Dec 9, 2019 06:19AM Blueprint Medicines (BPMC) Highlights Initial Data from Phase 2 PIONEER Trial of Avapritinib
Dec 8, 2019 09:00AM Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested
Nov 14, 2019 08:00AM Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference
Nov 6, 2019 09:00AM Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
Nov 5, 2019 07:00AM Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
Oct 29, 2019 08:00AM Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019
Oct 28, 2019 08:01AM Blueprint Medicines (BPMC) Announces FDA Intent to Split Avapritinib NDA into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Oct 28, 2019 08:00AM Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Oct 16, 2019 01:00AM Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Aug 28, 2019 08:00AM Blueprint Medicines to Present at Upcoming Investor Conferences in September
Aug 7, 2019 08:11AM Blueprint Medicines (BPMC) Announces FDA Acceptance of NDA for Avapritinib for Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Aug 7, 2019 08:00AM Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Aug 6, 2019 08:00AM Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference
View More Recent Stories View Older Stories